Archived: 13th Winter Conference
on Medicinal & Bioorganic Chemistry

January 22nd - 26th 2017

Steamboat Springs Resort, Colorado


Sunday, January 22nd 2017

MBCF Drughunter Award

Program Chair: Matthew M. Hayward, Pfizer

Dr Mark Flanagan Pfizer

Discovery of Xeljanz

Drug Discovery in Autoimmunity

Program Chair: Timothy Richardson & Daniel Dairaghi, Eli Lilly

Dr Penglie Zhang ChemoCentryx

CCR1 Antagonist

Dr James Crawford Genentech

Discovery of GDC-0853: A Highly Potent, Selective, and Non-Covalent Btk Inhibitor

Dr Linghang Zhuang Vitae Pharmaceuticals, Inc., an Allergan affiliate

Discovery of VTP-43742, A RORgt Inverse Agonist for the Treatment of Psoriasis

Dr Les Miranda Amgen

Peptide Antagonists of Kv1.3

Monday, January 23rd 2017

Liquid Biopsy Platforms as Biomarkers in Oncology Clinical Trials and as Companion Diagnostics

Program Chair: Daniel Flynn, Deciphera Pharmaceuticals

Dr Bryan Smith Deciphera Pharmaceuticals

Detecting Circulating Tumor Cells in Clinical Trials – Making Circulating Tumor Cells Glow using a Telomerase-based Assay

Mr Daniel Simon Guardant Health Inc.

Accelerating Clinical Trials using NGS Liquid Biopsy

Dr Robert Shoemaker Ignyta Inc.

Using ctDNA Biomarkers in Ignyta’s Clinical Trials: Detecting Activating Alterations, Monitoring Drug Efficacy, and Detecting Resistance Mechanisms

Dr Johan Skog Exosome Diagnostics

Bringing Exosome Liquid Biopsy Technology into the Realm of Routine Clinical Use

Dr Sid Scudder Roche Molecular Systems

Cell Free DNA Analysis of NSCLC Patients as a Paradigm for Clinical use of Liquid Biopsies

Advances in PET Imaging

Program Chair: Mike VanNieuwenhze, Indiana University / Shane Krsha, Merck

Dr Neil Vasdev Harvard Medical School

Cutting-Edge PET Radiochemistry Methodologies Applied to Drug Development

Dr Shane Krska Merck

Enabling Late Stage Fluorination Methods for the Discovery and Radiosynthesis of PET Imaging Agents

Dr Hartmuth Kolb Johnson & Johnson

Development of PET Imaging Tracers for Neuroscience Applications

Professor David Perrin University of British Columbia

Empowering Preclinical PET Imaging: Facile and User-Friendly 18F-labeling of Complex Molecules

Tuesday, January 24th 2017

Advances in Modern Synthetic Methods

Program Chair: Victor Snieckus, Queen’s University

Dr Gerald Tanoury Vertex

Converting a Medicinal Chemistry Synthesis into a Manufacturing Process

Dr Antonia Stepan Pfizer

C-H Functionalization Methods as Cutting-Edge Synthesis Tools for Medicinal Chemists

Dr Carl Busacca Boehringer Ingelheim

Hydrophosphinations of Strained Rings

Thieme and IUPAC Prize Lecture
Dr Neil Garg University of California

Recent Forays in Methods Development and Complex Molecule Synthesis

Post-Phenotypic Screen Target Identification

Program Chair: Philippe Nantermet & Scott Wolkenberg, Merck

Dr Monica Schenone Broad Inst

Target ID Successes and Lessons

Dr Donovan Chin Novartis

Computational Approaches to Target ID Using Large Scale Protein-Ligand Modeling

Dr Andrea Zuhl AstraZeneca

A Chemoproteomic Approach to Identify Drivers of BACE1 Inhibitor Ocular Toxicity

Dr Susanne Swalley Novartis

The Splice is Right: Phenotypic Drug Discovery and Target ID for Spinal Muscular Atrophy

Wednesday, January 25th 2017

Biophysical Tools in Drug Discovery and Chemical Biology

Program Chair: Lyn Jones, Pfizer

Professor Ralph Mazitschek Harvard University

Light-controlled Modulation of Gene Expression by Chemical Optoepigenetic Probes

Dr Gerard Drewes Cellzome / GlaxoSmithKline

Tracking Drug Action by Chemical Proteomics

Dr Matthew Clark X-Chem

Principles and Applications of DNA-Encoded Library Technologies

Dr Lyn Jones Pfizer

Biophysical and Chemical Methods to Interrogate Drug-Target Engagement

General Session | Medicinal and Synthetic Chemistry

Program Chair: Anthony Barrett, Imperial College / Matthew M. Hayward, Pfizer

Dr Petr Vachal Merck

Merck Drug Discovery Enabled

Dr Giles Brown Heptares

Structure-based drug design with G protein-coupled receptors: The discovery of Highly Selective M1 Agonists

Dr Ryan White Amgen

Accounting for Lysosomotropism as a Strategy for Prioritizing Selective Inhibitors of BACE

Dr Klemens Hoegenauer Novartis

The Discovery of a New Generation of Potent and Selective PI3Kδ Inhibitors

Dr Louis Chupak Bristol Myers Squibb

Chemically Non-Reactive Glycine Sulfonamide Inhibitors of Diacylglycerol Lipase

Dr Sarah Trice Sigma Aldrich

Modern Chemistry: Tools to Enable the Practicing Chemist

Dr Leonard Winneroski Eli Lilly

Preparation and Biological Evaluation of trans-Cyclopropyl-linked BACE1 Inhibitors

Thursday, January 26th 2017

Viral Diseases Eradication

Program Chair: Philippe G. Nantermet, Merck

Dr John McCauley Merck

Invention of Grazoprevir, a Hepatitis C NS3 Protease Inhibitor

Dr Will Watkins Gilead

Inhibition of the HCV Polymerase NS5B as a Means Towards Curative Therapy

Dr Nick Meanwell Bristol Myers Squib

The Discovery of HCV NS5A Replication Complex Inhibitors

Dr Mike Sofia Arbutus Biopharma, Inc.

Hepatitis B: Is There a Path to a Cure?

Dr Daria Hazuda Merck

What will it take to Eradicate HIV: A Drug Discovery Perspective


Program Chair: Professor Anthony GM Barrett, Imperial College

Dr Steven D. Young VP Basic Research (retired) Merck & Co.; Scientific Consultant and Acting Head of Chemistry, BeiGene LTD

Tackling a Pandemic Disease: A History of HIV Drug Discovery at Merck

Media Sponsors